Clotblog with Dr Samuel GoldhaberView all posts »
LIFENOX: No advantage of VTE prophylaxis in hospitalized medical service patientsJan 13, 2012 09:20 EST
The surprising results of the LIFENOX trial—which failed to show an advantage of daily enoxaparin vs placebo to reduce mortality in the acute-care setting—challenge dogma. What explains these results?
Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2012; 365:2463-2472. Abstract.